Axsome Therapeutics Stock Price, News & Analysis (NASDAQ:AXSM)

$2.70 +0.10 (+3.85 %)
(As of 02/19/2018 04:00 PM ET)
Previous Close$2.70
Today's Range$2.58 - $2.75
52-Week Range$2.45 - $6.45
Volume328,114 shs
Average Volume560,060 shs
Market Capitalization$68.71 million
P/E Ratio-1.99
Dividend YieldN/A
BetaN/A

About Axsome Therapeutics (NASDAQ:AXSM)

Axsome Therapeutics logoAxsome Therapeutics, Inc. is a clinical-stage biopharmaceutical company. The Company is engaged in developing therapies for the management of central nervous system (CNS) disorders, including pain. It operates in the business of developing novel therapies for the management of CNS disorders segment. Its product candidate, AXS-02 (disodium zoledronate tetrahydrate), is an oral, targeted, non opioid therapeutic for chronic pain. It is developing AXS 02 for the treatment of pain in over three conditions, such as complex regional pain syndrome (CRPS); knee osteoarthritis (OA) associated with bone marrow lesions (BMLs), and chronic low back pain (CLBP), associated with type I, or mixed type I and type II Modic changes (MCs). Its product candidate, AXS 05, is a fixed dose combination of dextromethorphan (DM) and bupropion. It is developing AXS 05 for the treatment of over two conditions, such as treatment resistant depression (TRD), and agitation in patients with Alzheimer's disease (AD).

Receive AXSM News and Ratings via Email

Sign-up to receive the latest news and ratings for AXSM and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Industry Bio Therapeutic Drugs
Sub-IndustryN/A
SectorHealthcare
SymbolNASDAQ:AXSM
CUSIPN/A
Phone+1-212-2035072

Debt

Debt-to-Equity Ratio0.44%
Current Ratio3.86%
Quick Ratio3.86%

Price-To-Earnings

Trailing P/E Ratio-1.98529411764706
Forward P/E Ratio-2.06
P/E GrowthN/A

Sales & Book Value

Annual SalesN/A
Price / SalesN/A
Cash FlowN/A
Price / CashN/A
Book Value$1.13 per share
Price / Book2.39

Profitability

Trailing EPS($1.36)
Net Income$-27,200,000.00
Net MarginsN/A
Return on Equity-127.58%
Return on Assets-73.83%

Miscellaneous

Employees22
Outstanding Shares25,450,000

Axsome Therapeutics (NASDAQ:AXSM) Frequently Asked Questions

What is Axsome Therapeutics' stock symbol?

Axsome Therapeutics trades on the NASDAQ under the ticker symbol "AXSM."

How were Axsome Therapeutics' earnings last quarter?

Axsome Therapeutics Inc (NASDAQ:AXSM) issued its earnings results on Wednesday, August, 9th. The company reported ($0.30) earnings per share for the quarter, topping the Zacks' consensus estimate of ($0.31) by $0.01. View Axsome Therapeutics' Earnings History.

When will Axsome Therapeutics make its next earnings announcement?

Axsome Therapeutics is scheduled to release their next quarterly earnings announcement on Monday, March, 5th 2018. View Earnings Estimates for Axsome Therapeutics.

Where is Axsome Therapeutics' stock going? Where will Axsome Therapeutics' stock price be in 2018?

4 brokerages have issued 12-month price objectives for Axsome Therapeutics' shares. Their predictions range from $13.00 to $31.00. On average, they expect Axsome Therapeutics' stock price to reach $19.50 in the next year. View Analyst Ratings for Axsome Therapeutics.

Are investors shorting Axsome Therapeutics?

Axsome Therapeutics saw a increase in short interest in the month of January. As of January 12th, there was short interest totalling 768,308 shares, an increase of 36.0% from the December 29th total of 565,070 shares. Based on an average daily volume of 1,175,697 shares, the short-interest ratio is currently 0.7 days. Currently, 4.8% of the shares of the stock are sold short.

Who are some of Axsome Therapeutics' key competitors?

Who are Axsome Therapeutics' key executives?

Axsome Therapeutics' management team includes the folowing people:

  • Herriot Tabuteau M.D., Chairman of the Board, Chief Executive Officer (Age 47)
  • John Golubieski, Chief Financial Officer (Age 52)
  • Constance Ames, Vice President - Finance (Age 29)
  • Mark Jacobson, Senior Director - Operations (Age 32)
  • Randall E. Kaye M.D., Chief Medical Officer (Age 53)
  • Robert Niecestro Ph.D., Head of Regulatory (Age 64)
  • Mark Coleman M.D., Independent Director (Age 47)
  • Roger A. Jeffs Ph.D., Independent Director (Age 55)
  • Myrtle S. Potter, Independent Director (Age 58)
  • Mark Saad, Independent Director

When did Axsome Therapeutics IPO?

(AXSM) raised $52 million in an IPO on Thursday, November 19th 2015. The company issued 4,300,000 shares at $11.00-$13.00 per share. Ladenburg Thalmann and Cantor Fitzgerald & Co. acted as the underwriters for the IPO and Brean Capital was co-manager.

Who owns Axsome Therapeutics stock?

Axsome Therapeutics' stock is owned by a number of of institutional and retail investors. Top institutional investors include SABBY MANAGEMENT, LLC (5.52%), Sphera Funds Management LTD. (1.18%), Millennium Management LLC (0.49%), Renaissance Technologies LLC (0.19%) and Goldman Sachs Group Inc. (0.17%). View Institutional Ownership Trends for Axsome Therapeutics.

Who sold Axsome Therapeutics stock? Who is selling Axsome Therapeutics stock?

Axsome Therapeutics' stock was sold by a variety of institutional investors in the last quarter, including Sphera Funds Management LTD. and Millennium Management LLC. View Insider Buying and Selling for Axsome Therapeutics.

Who bought Axsome Therapeutics stock? Who is buying Axsome Therapeutics stock?

Axsome Therapeutics' stock was acquired by a variety of institutional investors in the last quarter, including Renaissance Technologies LLC and Goldman Sachs Group Inc.. View Insider Buying and Selling for Axsome Therapeutics.

How do I buy Axsome Therapeutics stock?

Shares of Axsome Therapeutics can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is Axsome Therapeutics' stock price today?

One share of Axsome Therapeutics stock can currently be purchased for approximately $2.70.

How big of a company is Axsome Therapeutics?

Axsome Therapeutics has a market capitalization of $68.71 million. The company earns $-27,200,000.00 in net income (profit) each year or ($1.36) on an earnings per share basis. Axsome Therapeutics employs 22 workers across the globe.

How can I contact Axsome Therapeutics?

Axsome Therapeutics' mailing address is 25 Broadway Fl 9, NEW YORK, NY 10004-1058, United States. The company can be reached via phone at +1-212-2035072.


MarketBeat Community Rating for Axsome Therapeutics (AXSM)

Community Ranking:  2.8 out of 5 (star star)
Outperform Votes:  135 (Vote Outperform)
Underperform Votes:  105 (Vote Underperform)
Total Votes:  240
MarketBeat's community ratings are surveys of what our community members think about Axsome Therapeutics and other stocks. Vote "Outperform" if you believe the stock will outperform the S&P 500 over the long term. Vote "Underperform" if you believe the stock will underperform the S&P 500 over the long term. You may vote once every thirty days.

Analyst Ratings

Axsome Therapeutics (NASDAQ:AXSM) Analysts' Consensus Rating

  (How are Consensus Ratings Calculated?)
Today30 Days Ago90 Days Ago180 Days Ago
Consensus Rating: BuyBuyBuyBuy
Consensus Rating Score: 3.003.003.003.00
Ratings Breakdown: 0 Sell Rating(s)
0 Hold Rating(s)
4 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
0 Hold Rating(s)
4 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
0 Hold Rating(s)
4 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
0 Hold Rating(s)
5 Buy Rating(s)
0 Strong Buy Rating(s)
Consensus Price Target: $19.50$19.50$19.50$19.60
Price Target Upside: 245.13% upside245.13% upside242.11% upside243.86% upside

Axsome Therapeutics (NASDAQ:AXSM) Consensus Price Target History

Price Target History for Axsome Therapeutics (NASDAQ:AXSM)

Axsome Therapeutics (NASDAQ:AXSM) Analyst Ratings History

Show:
DateBrokerageActionRatingPrice TargetImpact on Share PriceDetails
12/1/2017Cantor FitzgeraldSet Price TargetBuy$13.00LowView Rating Details
7/26/2017Ladenburg Thalmann Financial ServicesReiterated RatingBuy$28.00 -> $31.00HighView Rating Details
6/20/2017AegisReiterated RatingBuy$20.00HighView Rating Details
5/19/2017BTIG ResearchInitiated CoverageBuy$14.00HighView Rating Details
10/3/2016Brean CapitalInitiated CoverageBuy$20.00N/AView Rating Details
(Data available from 2/19/2016 forward)

Earnings

Axsome Therapeutics (NASDAQ:AXSM) Earnings History and Estimates Chart

Earnings by Quarter for Axsome Therapeutics (NASDAQ:AXSM)

Axsome Therapeutics (NASDAQ AXSM) Earnings History by Quarter

DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
3/5/2018($0.33)N/AView Earnings Details
11/8/2017Q3 2017($0.27)ViewN/AView Earnings Details
8/9/2017Q2 2017($0.31)($0.30)ViewN/AView Earnings Details
5/9/20173/31/2017($0.40)($0.41)ViewN/AView Earnings Details
3/7/2017Q4 2016($0.38)ViewN/AView Earnings Details
11/14/2016Q3($0.39)($0.38)ViewN/AView Earnings Details
8/9/2016Q2 2016($0.39)($0.36)ViewN/AView Earnings Details
5/11/2016Q116($0.28)($0.31)ViewN/AView Earnings Details
3/24/2016Q416($0.22)($0.12)ViewN/AView Earnings Details
(Earnings results data provided by Zacks Investment Research)

Estimates

Axsome Therapeutics (NASDAQ:AXSM) Earnings Estimates

Current Year EPS Consensus Estimate: $-1.31 EPS
Next Year EPS Consensus Estimate: $-0.16 EPS

Dividends

Dividend History for Axsome Therapeutics (NASDAQ:AXSM)


No dividend announcements for this company have been tracked by MarketBeat.com

Insider Trades

Axsome Therapeutics (NASDAQ AXSM) Insider Trading and Institutional Ownership History

Insider Ownership Percentage: 35.20%
Institutional Ownership Percentage: 21.93%
Insider Trades by Quarter for Axsome Therapeutics (NASDAQ:AXSM)
Institutional Ownership by Quarter for Axsome Therapeutics (NASDAQ:AXSM)

Axsome Therapeutics (NASDAQ AXSM) Insider Trades by Quarter

Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionShares Held After TransactionDetails
12/23/2015Randall KayeInsiderBuy1,000$9.03$9,030.00View SEC Filing  
(Data available from 1/1/2013 forward)

Headlines

Axsome Therapeutics (NASDAQ AXSM) News Headlines

Source:
DateHeadline
Is Axsome Therapeutics Inc’s (NASDAQ:AXSM) Balance Sheet Strong Enough To Weather A Storm?Is Axsome Therapeutics Inc’s (NASDAQ:AXSM) Balance Sheet Strong Enough To Weather A Storm?
finance.yahoo.com - February 15 at 6:01 AM
Axsome Therapeutics Inc (AXSM) Receives Average Rating of "Buy" from BrokeragesAxsome Therapeutics Inc (AXSM) Receives Average Rating of "Buy" from Brokerages
www.americanbankingnews.com - February 3 at 3:26 AM
Axsome Therapeutics Inc (AXSM) Sees Large Increase in Short InterestAxsome Therapeutics Inc (AXSM) Sees Large Increase in Short Interest
www.americanbankingnews.com - January 28 at 1:26 AM
Mid-Day Market Update: Dow Surges Over 100 Points; e.l.f. Beauty Shares DropMid-Day Market Update: Dow Surges Over 100 Points; e.l.f. Beauty Shares Drop
www.nasdaq.com - January 9 at 3:40 PM
Mid-Morning Market Update: Markets Mostly Higher; Acuity Brands Profit Misses ViewsMid-Morning Market Update: Markets Mostly Higher; Acuity Brands Profit Misses Views
www.benzinga.com - January 9 at 11:10 AM
Axsome Therapeutics Announces AXS-02 Independent Data Monitoring Committee Recommends Continuation of COAST-1 Trial and Discontinuation of CREATE-1 TrialAxsome Therapeutics Announces AXS-02 Independent Data Monitoring Committee Recommends Continuation of COAST-1 Trial and Discontinuation of CREATE-1 Trial
finance.yahoo.com - January 9 at 11:10 AM
Axsome Therapeutics Inc (AXSM) Receives Consensus Rating of "Buy" from AnalystsAxsome Therapeutics Inc (AXSM) Receives Consensus Rating of "Buy" from Analysts
www.americanbankingnews.com - January 9 at 5:38 AM
Critical Survey: Axsome Therapeutics (AXSM) versus The CompetitionCritical Survey: Axsome Therapeutics (AXSM) versus The Competition
www.americanbankingnews.com - January 2 at 11:10 PM
Axsome Therapeutics (AXSM) Upgraded to "Buy" at Zacks Investment ResearchAxsome Therapeutics (AXSM) Upgraded to "Buy" at Zacks Investment Research
www.americanbankingnews.com - January 1 at 5:20 PM
Axsome Therapeutics Target of Unusually Large Options Trading (AXSM)Axsome Therapeutics Target of Unusually Large Options Trading (AXSM)
www.americanbankingnews.com - December 31 at 2:40 AM
Axsome Therapeutics (AXSM) Downgraded to Hold at Zacks Investment ResearchAxsome Therapeutics (AXSM) Downgraded to Hold at Zacks Investment Research
www.americanbankingnews.com - December 29 at 7:18 PM
Analyzing Axsome Therapeutics (AXSM) and Its PeersAnalyzing Axsome Therapeutics (AXSM) and Its Peers
www.americanbankingnews.com - December 26 at 5:48 AM
Axsome Therapeutics to Present at Biotech Showcase 2018 - GlobeNewswire (press release)Axsome Therapeutics to Present at Biotech Showcase 2018 - GlobeNewswire (press release)
globenewswire.com - December 21 at 11:28 AM
Reviewing Axsome Therapeutics (AXSM) and Its RivalsReviewing Axsome Therapeutics (AXSM) and Its Rivals
www.americanbankingnews.com - December 20 at 7:32 AM
Axsome Therapeutics to Present at Biotech Showcase 2018Axsome Therapeutics to Present at Biotech Showcase 2018
finance.yahoo.com - December 19 at 11:23 AM
Axsome Therapeutics Inc (AXSM) Given Consensus Rating of "Buy" by BrokeragesAxsome Therapeutics Inc (AXSM) Given Consensus Rating of "Buy" by Brokerages
www.americanbankingnews.com - December 15 at 3:32 AM
Axsome Therapeutics (AXSM) Rating Increased to Buy at Zacks Investment ResearchAxsome Therapeutics (AXSM) Rating Increased to Buy at Zacks Investment Research
www.americanbankingnews.com - December 14 at 4:56 PM
Axsome Therapeutics Collaborates with World-Leading Nicotine Addiction Research Center for Phase 2 Trial of AXS-05 in Smoking CessationAxsome Therapeutics Collaborates with World-Leading Nicotine Addiction Research Center for Phase 2 Trial of AXS-05 in Smoking Cessation
finance.yahoo.com - December 14 at 11:34 AM
Zacks Investment Research Downgrades Axsome Therapeutics (AXSM) to HoldZacks Investment Research Downgrades Axsome Therapeutics (AXSM) to Hold
www.americanbankingnews.com - December 13 at 4:46 PM
Axsome Therapeutics Announces Closing of $9.5 Million Registered Direct Offering - GlobeNewswire (press release)Axsome Therapeutics Announces Closing of $9.5 Million Registered Direct Offering - GlobeNewswire (press release)
globenewswire.com - December 6 at 8:46 AM
Axsome Therapeutics (AXSM) Reports 1.78M Share Registered Direct Offering Priced at the Market - StreetInsider.comAxsome Therapeutics (AXSM) Reports 1.78M Share Registered Direct Offering Priced at the Market - StreetInsider.com
www.streetinsider.com - December 3 at 3:40 PM
Cantor Fitzgerald Analysts Give Axsome Therapeutics (AXSM) a $13.00 Price TargetCantor Fitzgerald Analysts Give Axsome Therapeutics (AXSM) a $13.00 Price Target
www.americanbankingnews.com - December 1 at 6:24 PM
Axsome Therapeutics Announces $9.5 Million Registered Direct Offering Priced At-the-MarketAxsome Therapeutics Announces $9.5 Million Registered Direct Offering Priced At-the-Market
finance.yahoo.com - December 1 at 5:58 PM
Axsome Therapeutics, Inc. (AXSM) Receives Consensus Recommendation of "Buy" from BrokeragesAxsome Therapeutics, Inc. (AXSM) Receives Consensus Recommendation of "Buy" from Brokerages
www.americanbankingnews.com - November 20 at 3:58 AM
Axsome Therapeutics, Inc. (AXSM) Upgraded to "Buy" by Zacks Investment ResearchAxsome Therapeutics, Inc. (AXSM) Upgraded to "Buy" by Zacks Investment Research
www.americanbankingnews.com - November 15 at 5:06 PM
Axsome Therapeutics Reports Third Quarter 2017 Financial ResultsAxsome Therapeutics Reports Third Quarter 2017 Financial Results
www.thestreet.com - November 8 at 6:42 PM
Axsome Therapeutics, Inc. (AXSM) Scheduled to Post Quarterly Earnings on MondayAxsome Therapeutics, Inc. (AXSM) Scheduled to Post Quarterly Earnings on Monday
www.americanbankingnews.com - November 6 at 5:22 AM
Axsome Therapeutics (AXSM) and Kite Pharma (KITE) Critical SurveyAxsome Therapeutics (AXSM) and Kite Pharma (KITE) Critical Survey
www.americanbankingnews.com - October 31 at 7:16 PM
Axsome Therapeutics, Inc. (AXSM) Receives Average Rating of "Buy" from AnalystsAxsome Therapeutics, Inc. (AXSM) Receives Average Rating of "Buy" from Analysts
www.americanbankingnews.com - October 26 at 3:32 AM
Axsome Therapeutics, Inc. (AXSM) Lowered to "Hold" at Zacks Investment ResearchAxsome Therapeutics, Inc. (AXSM) Lowered to "Hold" at Zacks Investment Research
www.americanbankingnews.com - October 17 at 5:16 PM
Axsome Therapeutics to Present at Upcoming Investor ConferencesAxsome Therapeutics to Present at Upcoming Investor Conferences
finance.yahoo.com - October 5 at 2:17 PM
Reviewing Insmed (INSM) and Axsome Therapeutics (AXSM)Reviewing Insmed (INSM) and Axsome Therapeutics (AXSM)
www.americanbankingnews.com - October 5 at 6:50 AM
Axsome Therapeutics Inc (AXSM) Given Average Rating of "Buy" by BrokeragesAxsome Therapeutics Inc (AXSM) Given Average Rating of "Buy" by Brokerages
www.americanbankingnews.com - October 1 at 2:50 AM
Axsome Therapeutics (AXSM) Reports CREATE-1 Interim Analysis Expected Year-End 2017Axsome Therapeutics (AXSM) Reports CREATE-1 Interim Analysis Expected Year-End 2017
www.streetinsider.com - September 8 at 4:43 PM
Axsome reports 2Q lossAxsome reports 2Q loss
finance.yahoo.com - September 7 at 4:20 PM
Axsome Announces CREATE-1 Interim Analysis Expected Year-End 2017Axsome Announces CREATE-1 Interim Analysis Expected Year-End 2017
finance.yahoo.com - September 7 at 4:20 PM
Axsome Therapeutics, Inc. (AXSM) Given Consensus Rating of "Buy" by AnalystsAxsome Therapeutics, Inc. (AXSM) Given Consensus Rating of "Buy" by Analysts
www.americanbankingnews.com - September 6 at 2:28 AM
Axsome Therapeutics, Inc. (NASDAQ:AXSM) Receives Consensus Recommendation of "Buy" from AnalystsAxsome Therapeutics, Inc. (NASDAQ:AXSM) Receives Consensus Recommendation of "Buy" from Analysts
www.americanbankingnews.com - August 12 at 2:32 AM
Axsome Therapeutics, Inc. (AXSM) Posts Quarterly  Earnings Results, Beats Estimates By $0.01 EPSAxsome Therapeutics, Inc. (AXSM) Posts Quarterly Earnings Results, Beats Estimates By $0.01 EPS
www.americanbankingnews.com - August 10 at 3:42 PM
Axsome Therapeutics Reports Second Quarter 2017 Financial ResultsAxsome Therapeutics Reports Second Quarter 2017 Financial Results
globenewswire.com - August 9 at 4:27 PM
Axsome Therapeutics, Inc. (AXSM) to Release Quarterly Earnings on MondayAxsome Therapeutics, Inc. (AXSM) to Release Quarterly Earnings on Monday
www.americanbankingnews.com - July 31 at 8:05 AM
Axsome Therapeutics (AXSM) Buy Rating Reaffirmed at Ladenburg Thalmann Financial ServicesAxsome Therapeutics' (AXSM) Buy Rating Reaffirmed at Ladenburg Thalmann Financial Services
www.americanbankingnews.com - July 26 at 12:40 PM
Axsome Therapeutics Announces AXS-06 (MoSEIC™ Meloxicam and Esomeprazole) Meets Primary Endpoint in Phase 1 Clinical TrialAxsome Therapeutics Announces AXS-06 (MoSEIC™ Meloxicam and Esomeprazole) Meets Primary Endpoint in Phase 1 Clinical Trial
finance.yahoo.com - July 25 at 4:09 PM
Axsome Therapeutics, Inc. (AXSM) Given Average Rating of "Buy" by BrokeragesAxsome Therapeutics, Inc. (AXSM) Given Average Rating of "Buy" by Brokerages
www.americanbankingnews.com - July 18 at 1:53 PM
Axsome Therapeutics Initiates Phase 2/3 Trial of AXS-05 for Alzheimer’s Disease AgitationAxsome Therapeutics Initiates Phase 2/3 Trial of AXS-05 for Alzheimer’s Disease Agitation
finance.yahoo.com - July 17 at 4:37 PM
Axsome Therapeutics Appoints John Golubieski as Chief Financial OfficerAxsome Therapeutics Appoints John Golubieski as Chief Financial Officer
feeds.benzinga.com - July 6 at 7:38 AM
Axsome reports 1Q lossAxsome reports 1Q loss
marketbeat.com - May 9 at 9:56 AM
Axsome Therapeutics Reports First Quarter 2017 Financial ResultsAxsome Therapeutics Reports First Quarter 2017 Financial Results
globenewswire.com - May 9 at 9:05 AM
Axsome Therapeutics (AXSM) Receives FDA Fast Track Designation for AXS-05 for AD AgitationAxsome Therapeutics (AXSM) Receives FDA Fast Track Designation for AXS-05 for AD Agitation
www.streetinsider.com - May 8 at 3:40 PM
Axsome Therapeutics (AXSM) Announces 3.74M Share Pricing at $3.74Axsome Therapeutics (AXSM) Announces 3.74M Share Pricing at $3.74
www.streetinsider.com - March 21 at 9:11 PM

SEC Filings

Axsome Therapeutics (NASDAQ:AXSM) SEC Filings

This page is loading this company's SEC Filings. Please wait...

Social Media

Financials

Axsome Therapeutics (NASDAQ:AXSM) Income Statement, Balance Sheet and Cash Flow Statement

Chart

Axsome Therapeutics (NASDAQ AXSM) Stock Chart for Monday, February, 19, 2018

Loading chart…

This page was last updated on 2/19/2018 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.